Genmab technology to put pressure on copyists
The most recent technology from Genmab, the so-called HexaBody platform, could play a significant role in Big Pharma’s battle against generics manufacturers in the future, says the company’s CEO.
by Benjamin Werner Christensen
Expectations are great for the HexaBody platform, designed to increase the effect of antibody treatments. Current blockbusters, and even abandoned candidate drugs, could turn out to be a future goldmine for the Danish developer of the technology, Genmab.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Genmab to expand Arzerra
For abonnenter
Genmab-CEO: Drug could be ready in 2016
For abonnenter
